5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Serious O
Infections O
: O
Do O
not O
start O
SIMPONI O
during O
an O
active O
infection O
. O

If O
an O
infection O
develops O
, O
monitor O
carefully O
, O
and O
stop O
SIMPONI O
if O
infection O
becomes O
serious O
( O
5.1 O
) O
* O
Invasive O
Fungal O
Infections O
: O
For O
patients O
who O
develop O
a O
systemic O
illness O
on O
SIMPONI O
, O
consider O
empiric O
antifungal O
therapy O
for O
those O
who O
reside O
in O
or O
travel O
to O
regions O
where O
mycoses O
are O
endemic O
( O
5.1 O
) O
* O
Hepatitis O
B O
Reactivation O
: O
Monitor O
HBV O
carriers O
during O
and O
several O
months O
after O
therapy O
. O

If O
reactivation O
occurs O
, O
stop O
SIMPONI O
and O
begin O
antiviral O
therapy O
( O
5.1 O
) O
* O
Malignancies O
: O
Incidence O
of O
lymphoma O
was O
greater O
than O
in O
the O
general O
U.S O
. O
population O
. O

Cases O
of O
other O
malignancies O
have O
been O
observed O
among O
patients O
receiving O
TNF O
blockers O
( O
5.2 O
) O
* O
Congestive O
Heart O
Failure O
: O
Worsening O
, O
or O
new O
onset O
, O
may O
occur O
. O

Stop O
SIMPONI O
if O
new O
or O
worsening O
symptoms O
occur O
( O
5.3 O
) O
* O
Demyelinating O
Disorders O
: O
Exacerbation O
or O
new O
onset O
may O
occur O
( O
5.4 O
) O
* O
Lupus-like O
Syndrome O
: O
Discontinue O
SIMPONI O
if O
symptoms O
develop O
( O
5.5 O
) O
* O
Hypersensitivity O
Reactions O
: O
Serious O
systemic O
hypersensitivity O
reactions O
including O
anaphylaxis O
may O
occur O
( O
5.11 O
) O
5.1 O
Serious O
Infections O
Patients O
treated O
with O
SIMPONI O
are O
at O
increased O
risk O
for O
developing O
serious O
infections B-OSE_Labeled_AE
involving O
various O
organ O
systems O
and O
sites O
that O
may O
lead O
to O
hospitalization O
or O
death B-NonOSE_AE
. O

Opportunistic B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
due I-OSE_Labeled_AE
to I-OSE_Labeled_AE
bacterial I-OSE_Labeled_AE
, O
mycobacterial O
, O
invasive O
fungal O
, O
viral O
, O
or O
parasitic O
organisms I-OSE_Labeled_AE
including O
aspergillosis B-OSE_Labeled_AE
, O
blastomycosis B-OSE_Labeled_AE
, O
candidiasis B-OSE_Labeled_AE
, O
coccidioidomycosis B-OSE_Labeled_AE
, O
histoplasmosis B-OSE_Labeled_AE
, O
legionellosis B-OSE_Labeled_AE
, O
listeriosis B-OSE_Labeled_AE
, O
pneumocystosis B-OSE_Labeled_AE
, O
and O
tuberculosis B-OSE_Labeled_AE
have O
been O
reported O
with O
TNF O
blockers O
. O

Patients O
have O
frequently O
presented O
with O
disseminated O
rather O
than O
localized O
disease O
. O

The O
concomitant O
use O
of O
a O
TNF O
blocker O
and O
abatacept O
or O
anakinra O
was O
associated O
with O
a O
higher O
risk O
of O
serious O
infections B-NonOSE_AE
; O
therefore O
, O
the O
concomitant O
use O
of O
SIMPONI O
and O
these O
biologic O
products O
is O
not O
recommended O
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
, O
5.7 O
) O
and O
Drug O
Interactions O
( O
7.2 O
) O
] O
. O

Treatment O
with O
SIMPONI O
should O
not O
be O
initiated O
in O
patients O
with O
an O
active B-Not_AE_Candidate
infection I-Not_AE_Candidate
, O
including O
clinically O
important O
localized B-Not_AE_Candidate
infections I-Not_AE_Candidate
. O

Patients O
greater O
than O
65 O
years O
of O
age O
, O
patients O
with O
co-morbid O
conditions O
and/or O
patients O
taking O
concomitant O
immunosuppressants B-NonOSE_AE
such O
as O
corticosteroids O
or O
methotrexate O
may O
be O
at O
greater O
risk O
of O
infection B-NonOSE_AE
. O

Consider O
the O
risks O
and O
benefits O
of O
treatment O
prior O
to O
initiating O
SIMPONI O
in O
patients O
: O
* O
with O
chronic O
or O
recurrent O
infection B-Not_AE_Candidate
; O
* O
who O
have O
been O
exposed B-Not_AE_Candidate
to I-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
; O
* O
with O
a O
history O
of O
an O
opportunistic B-Not_AE_Candidate
infection I-Not_AE_Candidate
; O
* O
who O
have O
resided O
or O
traveled O
in O
areas O
of O
endemic O
tuberculosis B-NonOSE_AE
or O
endemic O
mycoses B-NonOSE_AE
, O
such O
as O
histoplasmosis B-NonOSE_AE
, O
coccidioidomycosis B-NonOSE_AE
, O
or O
blastomycosis B-NonOSE_AE
; O
or O
* O
with O
underlying O
conditions O
that O
may O
predispose B-Not_AE_Candidate
them I-Not_AE_Candidate
to I-Not_AE_Candidate
infection I-Not_AE_Candidate
. O

Monitoring O
Closely O
monitor O
patients O
for O
the O
development O
of O
signs O
and O
symptoms O
of O
infection B-NonOSE_AE
during O
and O
after O
treatment O
with O
SIMPONI O
. O

Discontinue O
SIMPONI O
if O
a O
patient O
develops O
a O
serious O
infection B-NonOSE_AE
, O
an O
opportunistic B-NonOSE_AE
infection I-NonOSE_AE
, O
or O
sepsis B-NonOSE_AE
. O

For O
a O
patient O
who O
develops O
a O
new O
infection B-NonOSE_AE
during O
treatment O
with O
SIMPONI O
, O
perform O
a O
prompt O
and O
complete O
diagnostic O
workup O
appropriate O
for O
an O
immunocompromised B-NonOSE_AE
patient O
, O
initiate O
appropriate O
antimicrobial O
therapy O
, O
and O
closely O
monitor O
them O
. O

Serious O
Infection O
in O
Clinical O
Trials O
In O
controlled O
Phase O
3 O
trials O
through O
Week O
16 O
in O
patients O
with O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
, O
and O
AS B-Not_AE_Candidate
, O
serious O
infections B-OSE_Labeled_AE
were O
observed O
in O
1.4 O
% O
of O
SIMPONI-treated O
patients O
and O
1.3 O
% O
of O
control-treated O
patients O
. O

In O
the O
controlled O
Phase O
3 O
trials O
through O
Week O
16 O
in O
patients O
with O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
, O
and O
AS B-Not_AE_Candidate
, O
the O
incidence O
of O
serious O
infections B-OSE_Labeled_AE
per O
100 O
patient-years O
of O
follow-up O
was O
5.7 O
( O
95 O
% O
CI O
: O
3.8 O
, O
8.2 O
) O
for O
the O
SIMPONI O
group O
and O
4.2 O
( O
95 O
% O
CI O
: O
1.8 O
, O
8.2 O
) O
for O
the O
placebo O
group O
. O

In O
the O
controlled O
Phase O
2/3 O
trial O
through O
Week O
6 O
of O
SIMPONI O
induction O
in O
UC B-Not_AE_Candidate
, O
the O
incidence O
of O
serious O
infections B-OSE_Labeled_AE
in O
SIMPONI O
200/100 O
mg-treated O
patients O
was O
similar O
to O
the O
incidence O
of O
serious O
infections B-OSE_Labeled_AE
in O
placebo-treated O
patients O
. O

Through O
Week O
60 O
, O
the O
incidence O
of O
serious O
infections B-OSE_Labeled_AE
was O
similar O
in O
patients O
who O
received O
SIMPONI O
induction O
and O
100 O
mg O
during O
maintenance O
compared O
with O
patients O
who O
received O
SIMPONI O
induction O
and O
placebo O
during O
the O
maintenance O
portion O
of O
the O
UC B-Not_AE_Candidate
trial O
. O

Serious O
infections B-OSE_Labeled_AE
observed O
in O
SIMPONI-treated O
patients O
included O
sepsis B-OSE_Labeled_AE
, O
pneumonia B-OSE_Labeled_AE
, O
cellulitis B-OSE_Labeled_AE
, O
abscess B-OSE_Labeled_AE
, O
tuberculosis B-OSE_Labeled_AE
, O
invasive B-OSE_Labeled_AE
fungal I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
, O
and O
hepatitis B-OSE_Labeled_AE
B I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
. O

Tuberculosis O
Cases O
of O
reactivation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
tuberculosis I-OSE_Labeled_AE
or O
new O
tuberculosis B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
have O
been O
observed O
in O
patients O
receiving O
TNF O
blockers O
, O
including O
patients O
who O
have O
previously O
received O
treatment O
for O
latent B-Not_AE_Candidate
or O
active O
tuberculosis I-Not_AE_Candidate
. O

Evaluate O
patients O
for O
tuberculosis B-NonOSE_AE
risk O
factors O
and O
test O
for O
latent B-NonOSE_AE
infection I-NonOSE_AE
prior O
to O
initiating O
SIMPONI O
and O
periodically O
during O
therapy O
. O

Treatment O
of O
latent B-NonOSE_AE
tuberculosis I-NonOSE_AE
infection I-NonOSE_AE
prior O
to O
therapy O
with O
TNF O
blockers O
has O
been O
shown O
to O
reduce O
the O
risk O
of O
tuberculosis B-NonOSE_AE
reactivation I-NonOSE_AE
during O
therapy O
. O

Prior O
to O
initiating O
SIMPONI O
, O
assess O
if O
treatment O
for O
latent B-NonOSE_AE
tuberculosis I-NonOSE_AE
is O
needed O
; O
an O
induration O
of O
5 O
mm O
or O
greater O
is O
a O
positive B-NonOSE_AE
tuberculin I-NonOSE_AE
skin I-NonOSE_AE
test I-NonOSE_AE
, O
even O
for O
patients O
previously O
vaccinated O
with O
Bacille B-NonOSE_AE
Calmette I-NonOSE_AE
- I-NonOSE_AE
Guerin I-NonOSE_AE
( I-NonOSE_AE
BCG I-NonOSE_AE
) O
. O

Consider O
anti B-NonOSE_AE
- I-NonOSE_AE
tuberculosis I-NonOSE_AE
therapy O
prior O
to O
initiation O
of O
SIMPONI O
in O
patients O
with O
a O
past O
history O
of O
latent B-Not_AE_Candidate
or O
active O
tuberculosis I-Not_AE_Candidate
in O
whom O
an O
adequate O
course O
of O
treatment O
can O
not O
be O
confirmed O
, O
and O
for O
patients O
with O
a O
negative B-Not_AE_Candidate
test I-Not_AE_Candidate
for I-Not_AE_Candidate
latent I-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
but O
having O
risk O
factors O
for O
tuberculosis B-Not_AE_Candidate
infection I-Not_AE_Candidate
. O

Consultation O
with O
a O
physician O
with O
expertise O
in O
the O
treatment O
of O
tuberculosis B-NonOSE_AE
is O
recommended O
to O
aid O
in O
the O
decision O
whether O
initiating O
anti B-NonOSE_AE
- I-NonOSE_AE
tuberculosis I-NonOSE_AE
therapy O
is O
appropriate O
for O
an O
individual O
patient O
. O

Cases O
of O
active B-OSE_Labeled_AE
tuberculosis I-OSE_Labeled_AE
have O
occurred O
in O
patients O
treated O
with O
SIMPONI O
during O
and O
after O
treatment O
for O
latent B-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
. O

Monitor O
patients O
for O
the O
development O
of O
signs O
and O
symptoms O
of O
tuberculosis B-NonOSE_AE
including O
patients O
who O
tested O
negative B-NonOSE_AE
for I-NonOSE_AE
latent I-NonOSE_AE
tuberculosis I-NonOSE_AE
infection I-NonOSE_AE
prior O
to O
initiating O
therapy O
, O
patients O
who O
are O
on O
treatment O
for O
latent B-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
, O
or O
patients O
who O
were O
previously O
treated O
for O
tuberculosis B-Not_AE_Candidate
infection I-Not_AE_Candidate
. O

Consider O
tuberculosis B-NonOSE_AE
in O
the O
differential O
diagnosis O
in O
patients O
who O
develop O
a O
new O
infection B-NonOSE_AE
during O
SIMPONI O
treatment O
, O
especially O
in O
patients O
who O
have O
previously O
or O
recently O
traveled O
to O
countries O
with O
a O
high O
prevalence O
of O
tuberculosis B-NonOSE_AE
, O
or O
who O
have O
had O
close O
contact O
with O
a O
person O
with O
active B-NonOSE_AE
tuberculosis I-NonOSE_AE
. O

In O
the O
controlled O
and O
uncontrolled O
portions O
of O
the O
Phase O
2 O
RA B-Not_AE_Candidate
and O
Phase O
3 O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
, O
and O
AS B-Not_AE_Candidate
trials O
, O
the O
incidence O
of O
active B-OSE_Labeled_AE
TB I-OSE_Labeled_AE
was O
0.23 O
and O
0 O
per O
100 O
patient-years O
in O
2347 O
SIMPONI-treated O
patients O
and O
674 O
placebo-treated O
patients O
, O
respectively O
. O

Cases O
of O
TB B-OSE_Labeled_AE
included O
pulmonary B-OSE_Labeled_AE
and O
extrapulmonary O
TB I-OSE_Labeled_AE
. O

The O
overwhelming O
majority O
of O
the O
TB B-NonOSE_AE
cases O
occurred O
in O
countries O
with O
a O
high O
incidence O
rate O
of O
TB B-NonOSE_AE
. O

In O
the O
controlled O
Phase O
2/3 O
trial O
of O
SIMPONI O
induction O
through O
Week O
6 O
in O
UC B-Not_AE_Candidate
, O
no O
cases O
of O
TB B-NonOSE_AE
were O
observed O
in O
SIMPONI O
200/100 O
mg-treated O
patients O
or O
in O
placebo-treated O
patients O
. O

Through O
Week O
60 O
, O
the O
incidence O
per O
100 O
patient-years O
of O
TB B-OSE_Labeled_AE
in O
patients O
who O
received O
SIMPONI O
induction O
and O
100 O
mg O
during O
the O
maintenance O
portion O
of O
the O
UC B-Not_AE_Candidate
trial O
was O
0.52 O
( O
95 O
% O
CI O
: O
0.11 O
, O
1.53 O
) O
. O

One O
case O
of O
TB B-OSE_Labeled_AE
was O
observed O
in O
the O
placebo O
maintenance O
group O
in O
a O
patient O
who O
received O
SIMPONI O
intravenous O
( O
IV O
) O
induction O
. O

Invasive B-OSE_Labeled_AE
Fungal I-OSE_Labeled_AE
Infections I-OSE_Labeled_AE
If O
patients O
develop O
a O
serious O
systemic B-NonOSE_AE
illness I-NonOSE_AE
and O
they O
reside O
or O
travel O
in O
regions O
where O
mycoses B-NonOSE_AE
are O
endemic O
, O
consider O
invasive B-NonOSE_AE
fungal I-NonOSE_AE
infection I-NonOSE_AE
in O
the O
differential O
diagnosis O
. O

Consider O
appropriate O
empiric O
antifungal O
therapy O
, O
and O
take O
into O
account O
both O
the O
risk O
for O
severe O
fungal B-NonOSE_AE
infection I-NonOSE_AE
and O
the O
risks O
of O
antifungal O
therapy O
while O
a O
diagnostic O
workup O
is O
being O
performed O
. O

Antigen B-NonOSE_AE
and O
antibody O
testing I-NonOSE_AE
for I-NonOSE_AE
histoplasmosis I-NonOSE_AE
may I-NonOSE_AE
be I-NonOSE_AE
negative I-NonOSE_AE
in O
some O
patients O
with O
active B-NonOSE_AE
infection I-NonOSE_AE
. O

To O
aid O
in O
the O
management O
of O
such O
patients O
, O
consider O
consultation O
with O
a O
physician O
with O
expertise O
in O
the O
diagnosis O
and O
treatment O
of O
invasive B-NonOSE_AE
fungal I-NonOSE_AE
infections I-NonOSE_AE
. O

Hepatitis O
B O
Virus O
Reactivation O
The O
use O
of O
TNF O
blockers O
including O
SIMPONI O
has O
been O
associated O
with O
reactivation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
hepatitis I-OSE_Labeled_AE
B I-OSE_Labeled_AE
virus I-OSE_Labeled_AE
( I-OSE_Labeled_AE
HBV I-OSE_Labeled_AE
) O
in O
patients O
who O
are O
chronic B-Not_AE_Candidate
hepatitis I-Not_AE_Candidate
B I-Not_AE_Candidate
carriers I-Not_AE_Candidate
( I-Not_AE_Candidate
i I-Not_AE_Candidate
. I-Not_AE_Candidate
e I-Not_AE_Candidate
. I-Not_AE_Candidate
, I-Not_AE_Candidate
surface I-Not_AE_Candidate
antigen I-Not_AE_Candidate
positive I-Not_AE_Candidate
) O
. O

In O
some O
instances O
, O
HBV B-NonOSE_AE
reactivation I-NonOSE_AE
occurring O
in O
conjunction O
with O
TNF O
blocker O
therapy O
has O
been O
fatal B-NonOSE_AE
. O

The O
majority O
of O
these O
reports O
have O
occurred O
in O
patients O
who O
received O
concomitant O
immunosuppressants B-NonOSE_AE
. O

All O
patients O
should O
be O
tested O
for O
HBV B-NonOSE_AE
infection I-NonOSE_AE
before O
initiating O
TNF-blocker O
therapy O
. O

For O
patients O
who O
test O
positive B-NonOSE_AE
for I-NonOSE_AE
hepatitis I-NonOSE_AE
B I-NonOSE_AE
surface I-NonOSE_AE
antigen I-NonOSE_AE
, O
consultation O
with O
a O
physician O
with O
expertise O
in O
the O
treatment O
of O
hepatitis B-NonOSE_AE
B I-NonOSE_AE
is O
recommended O
before O
initiating O
TNF-blocker O
therapy O
. O

The O
risks O
and O
benefits O
of O
treatment O
should O
be O
considered O
prior O
to O
prescribing O
TNF O
blockers O
, O
including O
SIMPONI O
, O
to O
patients O
who O
are O
carriers B-Not_AE_Candidate
of I-Not_AE_Candidate
HBV I-Not_AE_Candidate
. O

Adequate O
data O
are O
not O
available O
on O
whether O
antiviral O
therapy O
can O
reduce O
the O
risk O
of O
HBV B-NonOSE_AE
reactivation I-NonOSE_AE
in O
HBV B-Not_AE_Candidate
carriers I-Not_AE_Candidate
who O
are O
treated O
with O
TNF O
blockers O
. O

Patients O
who O
are O
carriers B-Not_AE_Candidate
of I-Not_AE_Candidate
HBV I-Not_AE_Candidate
and O
require O
treatment O
with O
TNF O
blockers O
should O
be O
closely O
monitored O
for O
clinical O
and O
laboratory O
signs O
of O
active O
HBV B-NonOSE_AE
infection I-NonOSE_AE
throughout O
therapy O
and O
for O
several O
months O
following O
termination O
of O
therapy O
. O

In O
patients O
who O
develop O
HBV B-NonOSE_AE
reactivation I-NonOSE_AE
, O
TNF O
blockers O
should O
be O
stopped O
and O
antiviral O
therapy O
with O
appropriate O
supportive O
treatment O
should O
be O
initiated O
. O

The O
safety O
of O
resuming O
TNF O
blockers O
after O
HBV B-NonOSE_AE
reactivation I-NonOSE_AE
has O
been O
controlled O
is O
not O
known O
. O

Therefore O
, O
prescribers O
should O
exercise O
caution O
when O
considering O
resumption O
of O
TNF O
blockers O
in O
this O
situation O
and O
monitor O
patients O
closely O
. O

5.2 O
Malignancies O
Malignancies B-OSE_Labeled_AE
, O
some O
fatal B-NonOSE_AE
, O
have O
been O
reported O
among O
children O
, O
adolescents O
, O
and O
young O
adults O
who O
received O
treatment O
with O
TNF-blocking O
agents O
( O
initiation O
of O
therapy O
< O
= O
18 O
years O
of O
age O
) O
, O
of O
which O
SIMPONI O
is O
a O
member O
. O

Approximately O
half O
the O
cases O
were O
lymphomas B-OSE_Labeled_AE
, O
including O
Hodgkin B-OSE_Labeled_AE
' I-OSE_Labeled_AE
s I-OSE_Labeled_AE
and O
non-Hodgkin O
's O
lymphoma I-OSE_Labeled_AE
. O

The O
other O
cases O
represented O
a O
variety O
of O
malignancies B-OSE_Labeled_AE
, O
including O
rare O
malignancies B-OSE_Labeled_AE
that O
are O
usually O
associated O
with O
immunosuppression B-NonOSE_AE
, O
and O
malignancies B-OSE_Labeled_AE
that O
are O
not O
usually O
observed O
in O
children O
and O
adolescents O
. O

The O
malignancies B-OSE_Labeled_AE
occurred O
after O
a O
median O
of O
30 O
months O
( O
range O
1 O
to O
84 O
months O
) O
after O
the O
first O
dose O
of O
TNF-blocker O
therapy O
. O

Most O
of O
the O
patients O
were O
receiving O
concomitant O
immunosuppressants B-NonOSE_AE
. O

These O
cases O
were O
reported O
postmarketing O
and O
are O
derived O
from O
a O
variety O
of O
sources O
, O
including O
registries O
and O
spontaneous O
postmarketing O
reports O
. O

The O
risks O
and O
benefits O
of O
TNF-blocker O
treatment O
, O
including O
SIMPONI O
, O
should O
be O
considered O
prior O
to O
initiating O
therapy O
in O
patients O
with O
a O
known O
malignancy B-Not_AE_Candidate
other O
than O
a O
successfully O
treated O
nonmelanoma B-Not_AE_Candidate
skin I-Not_AE_Candidate
cancer I-Not_AE_Candidate
( I-Not_AE_Candidate
NMSC I-Not_AE_Candidate
) O
or O
when O
considering O
continuing O
a O
TNF-blocker O
in O
patients O
who O
develop O
a O
malignancy B-NonOSE_AE
. O

In O
the O
controlled O
portions O
of O
clinical O
trials O
of O
TNF O
blockers O
, O
including O
SIMPONI O
, O
more O
cases O
of O
lymphoma B-OSE_Labeled_AE
have O
been O
observed O
among O
patients O
receiving O
anti-TNF O
treatment O
compared O
with O
patients O
in O
the O
control O
groups O
. O

During O
the O
controlled O
portions O
of O
the O
Phase O
2 O
trials O
in O
RA B-Not_AE_Candidate
, O
and O
the O
Phase O
3 O
trials O
in O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
and O
AS B-Not_AE_Candidate
, O
the O
incidence O
of O
lymphoma B-OSE_Labeled_AE
per O
100 O
patient-years O
of O
follow-up O
was O
0.21 O
( O
95 O
% O
CI O
: O
0.03 O
, O
0.77 O
) O
in O
the O
combined O
SIMPONI O
group O
compared O
with O
an O
incidence O
of O
0 O
( O
95 O
% O
CI O
: O
0 O
, O
0.96 O
) O
in O
the O
placebo O
group O
. O

In O
the O
controlled O
and O
uncontrolled O
portions O
of O
these O
clinical O
trials O
in O
2347 O
SIMPONI-treated O
patients O
with O
a O
median O
follow-up O
of O
1.4 O
years O
, O
the O
incidence O
of O
lymphoma B-OSE_Labeled_AE
was O
3.8-fold O
higher O
than O
expected O
in O
the O
general O
U.S O
. O
population O
according O
to O
the O
SEER O
database O
( O
adjusted O
for O
age O
, O
gender O
, O
and O
race O
) O
. O

1 O
Through O
Week O
60 O
of O
the O
UC B-Not_AE_Candidate
trials O
, O
there O
were O
no O
cases O
of O
lymphoma B-NonOSE_AE
with O
SIMPONI O
. O

Patients O
with O
RA B-Not_AE_Candidate
and O
other O
chronic B-Not_AE_Candidate
inflammatory I-Not_AE_Candidate
diseases I-Not_AE_Candidate
, O
particularly O
patients O
with O
highly O
active O
disease O
and/or O
chronic O
exposure O
to O
immunosuppressant B-NonOSE_AE
therapies I-NonOSE_AE
, O
may O
be O
at O
higher O
risk O
( O
up O
to O
several O
fold O
) O
than O
the O
general O
population O
for O
the O
development O
of O
lymphoma B-NonOSE_AE
, O
even O
in O
the O
absence O
of O
TNF-blocking O
therapy O
. O

Cases O
of O
acute B-OSE_Labeled_AE
and O
chronic O
leukemia I-OSE_Labeled_AE
have O
been O
reported O
with O
TNF-blocker O
use O
, O
including O
SIMPONI O
, O
in O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
and O
other O
indications O
. O

Even O
in O
the O
absence O
of O
TNF-blocker O
therapy O
, O
patients O
with O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
may O
be O
at O
a O
higher O
risk O
( O
approximately O
2-fold O
) O
than O
the O
general O
population O
for O
the O
development O
of O
leukemia B-NonOSE_AE
. O

Rare O
postmarketing O
cases O
of O
hepatosplenic B-OSE_Labeled_AE
T I-OSE_Labeled_AE
- I-OSE_Labeled_AE
cell I-OSE_Labeled_AE
lymphoma I-OSE_Labeled_AE
( I-OSE_Labeled_AE
HSTCL I-OSE_Labeled_AE
) O
have O
been O
reported O
in O
patients O
treated O
with O
TNF-blocking O
agents O
. O

This O
rare O
type O
of O
T B-NonOSE_AE
- I-NonOSE_AE
cell I-NonOSE_AE
lymphoma I-NonOSE_AE
has O
a O
very O
aggressive O
disease O
course O
and O
is O
usually O
fatal B-NonOSE_AE
. O

Nearly O
all O
of O
the O
reported O
TNF O
blocker O
associated O
cases O
have O
occurred O
in O
patients O
with O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
or O
ulcerative B-Not_AE_Candidate
colitis I-Not_AE_Candidate
. O

The O
majority O
were O
in O
adolescent O
and O
young O
adult O
males O
. O

Almost O
all O
these O
patients O
had O
received O
treatment O
with O
azathioprine O
( O
AZA O
) O
or O
6-mercaptopurine O
( O
6-MP O
) O
concomitantly O
with O
a O
TNF O
blocker O
at O
or O
prior O
to O
diagnosis O
. O

The O
potential O
risk O
with O
the O
combination O
of O
AZA O
or O
6-MP O
and O
SIMPONI O
should O
be O
carefully O
considered O
. O

A O
risk O
for O
the O
development O
for O
hepatosplenic B-NonOSE_AE
T I-NonOSE_AE
- I-NonOSE_AE
cell I-NonOSE_AE
lymphoma I-NonOSE_AE
in O
patients O
treated O
with O
TNF O
blockers O
can O
not O
be O
excluded O
. O

During O
the O
controlled O
portions O
of O
the O
Phase O
2 O
trial O
in O
RA B-Not_AE_Candidate
, O
and O
the O
Phase O
3 O
trials O
in O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
and O
AS B-Not_AE_Candidate
, O
the O
incidence O
of O
malignancies B-NonOSE_AE
other O
than O
lymphoma B-NonOSE_AE
per O
100 O
patient-years O
of O
follow-up O
was O
not O
elevated O
in O
the O
combined O
SIMPONI O
group O
compared O
with O
the O
placebo O
group O
. O

In O
the O
controlled O
and O
uncontrolled O
portions O
of O
these O
trials O
, O
the O
incidence O
of O
malignancies B-NonOSE_AE
, O
other O
than O
lymphoma B-NonOSE_AE
, O
in O
SIMPONI-treated O
patients O
was O
similar O
to O
that O
expected O
in O
the O
general O
U.S O
. O
population O
according O
to O
the O
SEER O
database O
( O
adjusted O
for O
age O
, O
gender O
, O
and O
race O
) O
. O

1 O
In O
the O
6-week O
placebo-controlled O
portions O
of O
the O
SIMPONI O
Phase O
2/3 O
clinical O
trials O
in O
UC B-Not_AE_Candidate
, O
the O
incidence O
of O
non B-NonOSE_AE
- I-NonOSE_AE
lymphoma I-NonOSE_AE
malignancies I-NonOSE_AE
( O
excluding O
nonmelanoma B-NonOSE_AE
skin I-NonOSE_AE
cancer I-NonOSE_AE
) O
was O
similar O
between O
the O
SIMPONI O
and O
the O
placebo O
group O
. O

Through O
Week O
60 O
, O
the O
incidence O
of O
non B-NonOSE_AE
- I-NonOSE_AE
lymphoma I-NonOSE_AE
malignancies I-NonOSE_AE
( O
excluding O
nonmelanoma B-NonOSE_AE
skin I-NonOSE_AE
cancer I-NonOSE_AE
) O
was O
similar O
to O
the O
general O
U.S O
. O
population O
according O
to O
the O
SEER O
database O
( O
adjusted O
for O
age O
, O
gender O
, O
and O
race O
) O
. O

1 O
Short O
follow-up O
periods O
, O
such O
as O
those O
of O
one O
year O
or O
less O
in O
the O
studies O
above O
, O
may O
not O
adequately O
reflect O
the O
true O
incidence O
of O
malignancies B-NonOSE_AE
. O

It O
is O
not O
known O
if O
SIMPONI O
treatment O
influences O
the O
risk O
for O
developing O
dysplasia B-NonOSE_AE
or O
colon B-NonOSE_AE
cancer I-NonOSE_AE
. O

All O
patients O
with O
ulcerative B-Not_AE_Candidate
colitis I-Not_AE_Candidate
who O
are O
at O
increased O
risk O
for O
dysplasia B-NonOSE_AE
or O
colon B-NonOSE_AE
carcinoma I-NonOSE_AE
( O
for O
example O
, O
patients O
with O
long-standing O
ulcerative B-Not_AE_Candidate
colitis I-Not_AE_Candidate
or O
primary B-Not_AE_Candidate
sclerosing I-Not_AE_Candidate
cholangitis I-Not_AE_Candidate
) O
, O
or O
who O
had O
a O
prior O
history O
of O
dysplasia B-Not_AE_Candidate
or O
colon B-Not_AE_Candidate
carcinoma I-Not_AE_Candidate
should O
be O
screened O
for O
dysplasia B-NonOSE_AE
at O
regular O
intervals O
before O
therapy O
and O
throughout O
their O
disease O
course O
. O

This O
evaluation O
should O
include O
colonoscopy O
and O
biopsies O
per O
local O
recommendations O
. O

In O
patients O
with O
newly O
diagnosed O
dysplasia B-NonOSE_AE
treated O
with O
SIMPONI O
, O
the O
risks O
and O
benefits O
to O
the O
individual O
patient O
must O
be O
carefully O
reviewed O
and O
consideration O
should O
be O
given O
to O
whether O
therapy O
should O
be O
continued O
. O

Melanoma B-OSE_Labeled_AE
and O
Merkel B-OSE_Labeled_AE
cell I-OSE_Labeled_AE
carcinoma I-OSE_Labeled_AE
have O
been O
reported O
in O
patients O
treated O
with O
TNF-blocking O
agents O
, O
including O
SIMPONI O
. O

Periodic O
skin O
examination O
is O
recommended O
for O
all O
patients O
, O
particularly O
those O
with O
risk O
factors O
for O
skin B-NonOSE_AE
cancer I-NonOSE_AE
. O

In O
controlled O
trials O
of O
other O
TNF O
blockers O
in O
patients O
at O
higher O
risk O
for O
malignancies B-NonOSE_AE
( O
e.g. O
, O
patients O
with O
chronic B-Not_AE_Candidate
obstructive I-Not_AE_Candidate
pulmonary I-Not_AE_Candidate
disease I-Not_AE_Candidate
[ I-Not_AE_Candidate
COPD I-Not_AE_Candidate
] O
, O
patients O
with O
Wegener B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
granulomatosis I-Not_AE_Candidate
treated O
with O
concomitant O
cyclophosphamide O
) O
a O
greater O
portion O
of O
malignancies B-NonOSE_AE
occurred O
in O
the O
TNF-blocker O
group O
compared O
to O
the O
controlled O
group O
. O

In O
an O
exploratory O
1-year O
clinical O
trial O
evaluating O
the O
use O
of O
50 O
mg O
, O
100 O
mg O
, O
and O
200 O
mg O
of O
SIMPONI O
in O
309 O
patients O
with O
severe O
persistent O
asthma B-Not_AE_Candidate
, O
6 O
patients O
developed O
malignancies B-OSE_Labeled_AE
other O
than O
NMSC B-NonOSE_AE
in O
the O
SIMPONI O
groups O
compared O
to O
none O
in O
the O
control O
group O
. O

Three O
of O
the O
6 O
patients O
were O
in O
the O
200-mg O
SIMPONI O
group O
. O

5.3 O
Congestive O
Heart O
Failure O
Cases O
of O
worsening B-OSE_Labeled_AE
congestive I-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
( I-OSE_Labeled_AE
CHF I-OSE_Labeled_AE
) O
and O
new O
onset O
CHF B-OSE_Labeled_AE
have O
been O
reported O
with O
TNF O
blockers O
, O
including O
SIMPONI O
. O

Some O
cases O
had O
a O
fatal B-NonOSE_AE
outcome O
. O

In O
several O
exploratory O
trials O
of O
other O
TNF O
blockers O
in O
the O
treatment O
of O
CHF B-NonOSE_AE
, O
there O
were O
greater O
proportions O
of O
TNF-blocker-treated O
patients O
who O
had O
CHF B-NonOSE_AE
exacerbations I-NonOSE_AE
requiring O
hospitalization O
or O
increased O
mortality B-NonOSE_AE
. O

SIMPONI O
has O
not O
been O
studied O
in O
patients O
with O
a O
history O
of O
CHF B-Not_AE_Candidate
and O
SIMPONI O
should O
be O
used O
with O
caution O
in O
patients O
with O
CHF B-Not_AE_Candidate
. O

If O
a O
decision O
is O
made O
to O
administer O
SIMPONI O
to O
patients O
with O
CHF B-Not_AE_Candidate
, O
these O
patients O
should O
be O
closely O
monitored O
during O
therapy O
, O
and O
SIMPONI O
should O
be O
discontinued O
if O
new O
or O
worsening O
symptoms O
of O
CHF B-NonOSE_AE
appear O
. O

5.4 O
Demyelinating O
Disorders O
Use O
of O
TNF O
blockers O
, O
of O
which O
SIMPONI O
is O
a O
member O
, O
has O
been O
associated O
with O
rare O
cases O
of O
new O
onset O
or O
exacerbation O
of O
central B-OSE_Labeled_AE
nervous I-OSE_Labeled_AE
system I-OSE_Labeled_AE
( I-OSE_Labeled_AE
CNS I-OSE_Labeled_AE
) I-OSE_Labeled_AE
demyelinating I-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
, O
including O
multiple B-OSE_Labeled_AE
sclerosis I-OSE_Labeled_AE
( I-OSE_Labeled_AE
MS I-OSE_Labeled_AE
) O
and O
peripheral B-OSE_Labeled_AE
demyelinating I-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
, O
including O
Guillain B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Barre I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
. O

Cases O
of O
central B-OSE_Labeled_AE
demyelination I-OSE_Labeled_AE
, O
MS B-OSE_Labeled_AE
, O
optic B-OSE_Labeled_AE
neuritis I-OSE_Labeled_AE
, O
and O
peripheral B-OSE_Labeled_AE
demyelinating I-OSE_Labeled_AE
polyneuropathy I-OSE_Labeled_AE
have O
rarely O
been O
reported O
in O
patients O
treated O
with O
SIMPONI O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Prescribers O
should O
exercise O
caution O
in O
considering O
the O
use O
of O
TNF O
blockers O
, O
including O
SIMPONI O
, O
in O
patients O
with O
central B-Not_AE_Candidate
or O
peripheral O
nervous I-Not_AE_Candidate
system I-Not_AE_Candidate
demyelinating I-Not_AE_Candidate
disorders I-Not_AE_Candidate
. O

Discontinuation O
of O
SIMPONI O
should O
be O
considered O
if O
these O
disorders O
develop O
. O

5.5 O
Autoimmunity B-OSE_Labeled_AE
Treatment O
with O
TNF O
blockers O
, O
including O
SIMPONI O
, O
may O
result O
in O
the O
formation O
of O
antinuclear B-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ANA I-OSE_Labeled_AE
) O
and O
, O
rarely O
, O
in O
the O
development O
of O
a O
lupus B-OSE_Labeled_AE
- I-OSE_Labeled_AE
like I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

If O
a O
patient O
develops O
symptoms O
suggestive O
of O
a O
lupus B-NonOSE_AE
- I-NonOSE_AE
like I-NonOSE_AE
syndrome I-NonOSE_AE
following O
treatment O
with O
SIMPONI O
, O
treatment O
should O
be O
discontinued O
. O

5.6 O
Use O
with O
Abatacept O
In O
controlled O
trials O
, O
the O
concurrent O
administration O
of O
another O
TNF O
blocker O
and O
abatacept O
was O
associated O
with O
a O
greater O
proportion O
of O
serious O
infections B-NonOSE_AE
than O
the O
use O
of O
a O
TNF O
blocker O
alone O
; O
and O
the O
combination O
therapy O
, O
compared O
to O
the O
use O
of O
a O
TNF O
blocker O
alone O
, O
has O
not O
demonstrated O
improved O
clinical O
benefit O
in O
the O
treatment O
of O
RA B-Not_AE_Candidate
. O

Therefore O
, O
the O
combination O
of O
TNF O
blockers O
, O
including O
SIMPONI O
, O
and O
abatacept O
is O
not O
recommended O
[ O
see O
Drug O
Interactions O
( O
7.2 O
) O
] O
. O

5.7 O
Use O
with O
Anakinra O
Concurrent O
administration O
of O
anakinra O
( O
an O
interleukin-1 O
antagonist O
) O
and O
another O
TNF O
blocker O
was O
associated O
with O
a O
greater O
portion O
of O
serious O
infections B-NonOSE_AE
and O
neutropenia B-NonOSE_AE
and O
no O
additional O
benefits O
compared O
with O
the O
TNF-blocker O
alone O
. O

Therefore O
, O
the O
combination O
of O
anakinra O
with O
TNF O
blockers O
, O
including O
SIMPONI O
, O
is O
not O
recommended O
[ O
see O
Drug O
Interactions O
( O
7.2 O
) O
] O
. O

5.8 O
Switching O
Between O
Biological O
Disease-Modifying O
Antirheumatic O
Drugs O
Care O
should O
be O
taken O
when O
switching O
from O
one O
biological O
product O
to O
another O
biological O
product O
since O
overlapping O
biological O
activity O
may O
further O
increase O
the O
risk O
of O
infection B-NonOSE_AE
. O

5.9 O
Hematologic B-OSE_Labeled_AE
Cytopenias I-OSE_Labeled_AE
There O
have O
been O
postmarketing O
reports O
of O
pancytopenia B-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
aplastic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
, O
and O
thrombocytopenia B-OSE_Labeled_AE
in O
patients O
receiving O
TNF O
blockers O
. O

In O
clinical O
trials O
, O
cases O
of O
pancytopenia B-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
and O
thrombocytopenia B-OSE_Labeled_AE
have O
also O
occurred O
in O
SIMPONI-treated O
patients O
. O

Caution O
should O
be O
exercised O
when O
using O
TNF O
blockers O
, O
including O
SIMPONI O
, O
in O
patients O
who O
have O
or O
have O
had O
significant O
cytopenias B-Not_AE_Candidate
. O

5.10 O
Vaccinations/Therapeutic O
Infectious O
Agents O
Live O
Vaccines O
Patients O
treated O
with O
SIMPONI O
may O
receive O
vaccinations O
, O
except O
for O
live O
vaccines O
. O

In O
patients O
receiving O
anti-TNF O
therapy O
, O
limited O
data O
are O
available O
on O
the O
response O
to O
live O
vaccination O
, O
or O
on O
the O
secondary O
transmission O
of O
infection B-NonOSE_AE
by O
live O
vaccines O
. O

Use O
of O
live O
vaccines O
could O
result O
in O
clinical O
infections B-NonOSE_AE
, O
including O
disseminated B-NonOSE_AE
infections I-NonOSE_AE
. O

Therapeutic O
Infectious O
Agents O
Other O
uses O
of O
therapeutic B-NonOSE_AE
infectious I-NonOSE_AE
agents I-NonOSE_AE
such O
as O
live O
attenuated O
bacteria O
( O
e.g. O
, O
BCG O
bladder O
instillation O
for O
the O
treatment O
of O
cancer B-NonOSE_AE
) O
could O
result O
in O
clinical O
infections B-NonOSE_AE
, O
including O
disseminated B-NonOSE_AE
infections I-NonOSE_AE
. O

It O
is O
recommended O
that O
therapeutic O
infectious B-NonOSE_AE
agents O
not O
be O
given O
concurrently O
with O
SIMPONI O
. O

Non-live O
Vaccines O
In O
the O
Phase O
3 O
PsA B-Not_AE_Candidate
trial O
, O
after O
pneumococcal B-NonOSE_AE
vaccination I-NonOSE_AE
, O
a O
similar O
proportion O
of O
SIMPONI-treated O
and O
placebo-treated O
patients O
were O
able O
to O
mount B-NonOSE_AE
an I-NonOSE_AE
adequate I-NonOSE_AE
immune I-NonOSE_AE
response I-NonOSE_AE
of O
at O
least O
a O
2-fold O
increase B-NonOSE_AE
in I-NonOSE_AE
antibody I-NonOSE_AE
titers I-NonOSE_AE
to I-NonOSE_AE
pneumococcal I-NonOSE_AE
polysaccharide I-NonOSE_AE
vaccine I-NonOSE_AE
. O

In O
both O
SIMPONI-treated O
and O
placebo-treated O
patients O
, O
the O
proportions O
of O
patients O
with O
response O
to O
pneumococcal B-NonOSE_AE
vaccine I-NonOSE_AE
were O
lower O
among O
patients O
receiving O
MTX O
compared O
with O
patients O
not O
receiving O
MTX O
. O

The O
data O
suggest O
that O
SIMPONI O
does O
not O
suppress B-NonOSE_AE
the I-NonOSE_AE
humoral I-NonOSE_AE
immune I-NonOSE_AE
response I-NonOSE_AE
to O
the O
pneumococcal B-NonOSE_AE
vaccine I-NonOSE_AE
. O

5.11 O
Hypersensitivity O
Reactions O
In O
postmarketing O
experience O
, O
serious O
systemic O
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
including O
anaphylactic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
) O
have O
been O
reported O
following O
SIMPONI O
administration O
. O

Some O
of O
these O
reactions O
occurred O
after O
the O
first O
administration O
of O
SIMPONI O
. O

If O
an O
anaphylactic B-NonOSE_AE
or O
other O
serious O
allergic O
reaction I-NonOSE_AE
occurs O
, O
administration O
of O
SIMPONI O
should O
be O
discontinued O
immediately O
and O
appropriate O
therapy O
instituted O
. O

